The AKU Society, based in Cambridge UK, is one of the major partners in the DevelopAKUre consortium, we have been involved in the DevelopAKUre clinical trials since we helped found the consortium in 2012. Our role is to disseminate information about the trial, to recruit patie.. ...more
21 year old Nicole, flew all the way from Connecticut, USA to take part in the SOFIA Observational study last month. Here she tells us all about her reasons for taking part and her experiences coming to the Royal Liverpool University Hospital to take part in SOFIA .. ...more
Meet Pam Neagle, European Commission Coordinator for the Royal Liverpool University Hospital and Project Coordinator for the DevelopAKUre Consortium. What’s your role and what do you do for the DevelopAKUre consortium? I became involved in DevelopAKUre in March 2.. ...more
Professor Ranganath, the chief investigator of DeveleopAKUre, explains where we are with SONIA 2, the importance of SOFIA and why he enjoys working with AKU patients from all over the world. Now the 3rd visits are over for SONIA 2, what progress can you report? What are the next steps?.. ...more
DevelopAKUre is a series of major international clinical trials, run by a consortium of 12 European partners. It aims to study a potential new drug, called nitisinone, and assess its potential effectiveness in treating the rare disease, alkaptonuria (AKU).
DevelopAKUre is co-funded by a grant from the European Commission. This website is run by a UK patient group, the AKU Society. Learn more about AKU on the AKU Society's What is AKU page.
In today’s blog Chief investigator Prof. Ranganath reinforces the need for SONIA 2 pat.. ...more